Rejean Thomas
Overview
Explore the profile of Rejean Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galli R, Maraj D, McBain K, Lo Hog Tian J, McFarland A, Tharao W, et al.
BMC Public Health
. 2025 Jan;
25(1):125.
PMID: 39794710
Background: Blood and oral fluid-based HIV self-tests are important for reaching the undiagnosed living with HIV. The study objectives were to evaluate the oral fluid-based OraQuick® HIV Self-Test (HIV-ST) performance...
2.
Brenner B, Ibanescu R, Oliveira M, Margaillan G, Lebouche B, Thomas R, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205204
Background: HIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) in treatment and prevention. This study utilized viral phylogenetics to resolve the influence of transmission networks on...
3.
Avallone F, Engler K, Cox J, Hickson F, Lessard D, Bourdon J, et al.
Sex Health
. 2024 Jan;
21.
PMID: 38281508
Background: Gay, bisexual, and other men (GBM) who have sex with men living with HIV in serodifferent couples (one partner living with HIV, the other HIV-negative) may encounter unique sexual...
4.
Ramani H, Gosselin A, Bunet R, Jenabian M, Sylla M, Pagliuzza A, et al.
J Infect Dis
. 2023 Dec;
229(5):1277-1289.
PMID: 38113908
Interleukin 32 (IL-32) is a potent multi-isoform proinflammatory cytokine, which is upregulated in people with HIV (PWH) and is associated with cardiovascular disease (CVD) risk. However, the impact of IL-32...
5.
Doyle C, Milwid R, Cox J, Xia Y, Lambert G, Tremblay C, et al.
J Int AIDS Soc
. 2023 Dec;
26(12):e26194.
PMID: 38054579
Introduction: HIV pre-exposure prophylaxis (PrEP) has been recommended and partly subsidized in Québec, Canada, since 2013. We evaluated the population-level impact of PrEP on HIV transmission among men who have...
6.
Giguere K, Chartrand-Lefebvre C, Baril J, Conway B, El-Far M, Falutz J, et al.
HIV Med
. 2023 Oct;
24(12):1210-1221.
PMID: 37779267
Objectives: Our objective was to report the baseline characteristics of participants in the Canadian HIV and Aging Cohort Study (CHACS) and present amendments to the initial protocol. Methods: CHACS is...
7.
Bedier H, Isnard S, Thomas R, Routy J
Oxf Med Case Reports
. 2023 Jul;
2023(7):omad066.
PMID: 37484558
A 65-year-old woman successfully treated for human immunodeficiency virus (HIV) and Hepatitis C virus was diagnosed with porphyria cutanea tarda (PCT) and treated by phlebotomies. She developed extensive psoriatic skin...
8.
Brenner B, Oliveira M, Ibanescu R, Routy J, Thomas R
J Antimicrob Chemother
. 2023 Jun;
78(8):1921-1928.
PMID: 37303226
Objectives: The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used...
9.
Bunet R, Roy-Cardinal M, Ramani H, Cleret-Buhot A, Durand M, Chartrand-Lefebvre C, et al.
Viruses
. 2023 Mar;
15(3.
PMID: 36992409
Chronic inflammation is associated with higher risk of cardiovascular disease (CVD) in people living with HIV (PLWH). We have previously shown that interleukin-32 (IL-32), a multi-isoform proinflammatory cytokine, is chronically...
10.
Dufour C, Richard C, Pardons M, Massanella M, Ackaoui A, Murrell B, et al.
Nat Commun
. 2023 Feb;
14(1):1115.
PMID: 36849523
The phenotype of the rare HIV-infected cells persisting during antiretroviral therapies (ART) remains elusive. We developed a single-cell approach that combines the phenotypic analysis of HIV-infected cells with near full-length...